METTL3-mediated m6A modification of circMtmr7 contributes to paclitaxel-induced peripheral neuropathy in the dorsal

Chaopeng Ou1, Zhaoli He1,2, Sudena Wang1

  • 1Department of Anesthesiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Insights

Chemotherapy-induced peripheral neuropathy (CIPN) lacks treatments. This study reveals how METTL3 and circMtmr7 in the spinal cord amplify pain signals, identifying STAT5A and NUFIP2 as potential therapeutic targets for CIPN.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Oncology

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) presents a significant clinical challenge with limited disease-modifying therapies.
  • The underlying mechanisms of epitranscriptomic regulation in central sensitization during CIPN remain incompletely understood.

Purpose of the Study:

  • To elucidate the role of the METTL3-circRNA axis in paclitaxel-induced peripheral neuropathy (PIPN).
  • To investigate the downstream pathways involving circMtmr7, STAT5A, and NUFIP2 in mediating neuronal hyperexcitability and nociception.

Main Methods:

  • Utilized a mouse model of paclitaxel-induced peripheral neuropathy (PIPN).
  • Investigated the expression and function of METTL3, circMtmr7, STAT5A, and NUFIP2 in the spinal dorsal horn.
  • Employed techniques including gene knockdown, miRNA sponge assays, and assessment of neuronal excitability and behavioral nociceptive responses.

Main Results:

  • Upregulated METTL3 expanded the m6A-modified circMtmr7 pool in the spinal dorsal horn of paclitaxel-treated mice.
  • circMtmr7 enhanced NUFIP2 expression via cytoplasmic miRNA sponging and nuclear STAT5A association.
  • METTL3 knockdown or inhibition of circMtmr7, STAT5A, or NUFIP2 alleviated mechanical allodynia and normalized neuronal excitability.

Conclusions:

  • Established an m6A-dependent METTL3-circRNA-STAT5A-NUFIP2 axis that amplifies excitatory drive in PIPN.
  • This axis couples post-transcriptional and transcriptional regulation to drive central sensitization.
  • STAT5A and NUFIP2 are identified as promising therapeutic targets for managing CIPN.